Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Luxturna Market Size, Value And Growth Trends Through 2030
The expansion observed during the historical period is linked to the scarcity of treatment alternatives for inherited retinal conditions, progress made in viral vector development, initial regulatory clearances granted to gene-based therapies, a rise in financial support for rare disease studies, and the growing adoption of genetic testing methods.
The expansion of gene therapy pipelines, increased funding for rare disease treatments, wider use of early genetic screening, a stronger emphasis on long-term treatment results, and progress in retinal delivery technologies are fueling growth during the forecast period. Key developments shaping this period involve a surge in gene therapy adoption, heightened attention to rare genetic eye conditions, greater investment in single-dose curative approaches, the broadening of precision ophthalmology options, and improved merging of genetic testing with diagnostic processes.
Download A Free Sample Report For Comprehensive Market Insights:
Luxturna Market Growth Drivers: What Factors Are Accelerating Expansion?
The anticipated growth of the luxturna market is being driven by the increasing occurrence of genetic eye disorders. These disorders encompass a variety of inherited conditions resulting from gene mutations that impair the eyes’ structure or functionality, potentially causing visual impairments like blindness or diminished sight. Factors contributing to the higher prevalence of genetic eye disorders include a rise in genetic mutations, aging demographics, advancements in diagnostic tools, and heightened awareness of hereditary diseases. Luxturna functions as a gene therapy designed to address genetic eye disorders, particularly inherited retinal diseases (IRDs) triggered by RPE65 gene mutations, by introducing a working gene copy to potentially restore vision. For example, the United Nations Development Programme (UNDP), a US-based government agency, reported in December 2023 that 19,551 individuals were diagnosed with vision impairments in 2022, with over 19,000 new cases identified in just the first seven months of 2023. Consequently, the escalating prevalence of genetic eye disorders is fueling the expansion of the luxturna market.
Luxturna Market Driver: Rising Healthcare Expenditure To Accelerate Growth In Market
The luxturna market is expected to be propelled forward by increasing healthcare expenditure. Healthcare expenditure refers to the total funds allocated by governments, enterprises, or individuals for medical services, treatments, and products. This spending is on the rise due to factors such as aging populations, progress in medical technology, a growing burden of chronic illnesses, and escalating treatment expenses. Higher healthcare expenditure supports Luxturna by facilitating the funding and availability of advanced therapies like gene therapy for rare inherited retinal diseases, which typically come with high costs and demand specialized care. As an illustration, the Office for National Statistics, a UK-based government department, noted in May 2024 that healthcare expenditure saw a 5.6% nominal increase from 2022 to 2023, a notable acceleration compared to the 0.9% growth observed in 2022. Thus, a surge in healthcare expenditure is set to drive growth in the luxturna market.
Luxturna Market Segment Landscape: Which Areas Lead Market Development?
The luxturna market covered in this report is segmented –
1) By Indication: Treatment Of RPE65-Mediated Inherited Retinal Disease, Management Of Vision Loss
2) By Patient Demographics: Pediatric Patients, Adult Patients, Patients With Early Diagnosis
3) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
4) By End User: Hospitals, Ophthalmology Clinics, Specialty Pharmacies, Research Institutions
Luxturna Market Trends: What Is Shaping Future Industry Growth?
A prominent trend in the luxturna market involves the execution of real-world studies for its gene therapies, such as adeno-associated virus vector-based treatments, aimed at building a reputation for transparency and commitment to patient outcomes. In this approach, adeno-associated virus (AAV) vectors deliver therapeutic genes to cells via a modified virus, providing a treatment option for genetic disorders like RPE65-related retinal dystrophy. As an example, in April 2023, Spark Therapeutics, a US biotechnology firm focused on gene therapy, shared real-world data on Luxturna (voretigene neparvovec)—an AAV-based therapy for RPE65-related inherited retinal dystrophy (IRD)—gathered from eight Belgian patients at the ARVO 2023 Annual Meeting. The observational study evaluated 15 treated eyes, noting considerable improvements in light sensitivity to red, blue, and white light at six months post-treatment, alongside enhancements in the visual field (object III4). After two years, treatment with Luxturna resulted in a mean change of -0.03 in BCVA and a -13.67 decibel shift in the full-field light sensitivity threshold. On the safety front, 35% of patients reported at least one ocular adverse event, with chorioretinal atrophic changes emerging as the most frequent, observed in 13 cases.
Luxturna Market Industry Leaders And Market Competition
Major companies operating in the luxturna market are F. Hoffmann-La Roche AG
Access The Complete Luxturna Market Report:
Luxturna Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the luxturna market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the luxturna market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model